phase 2
study 2
frontline 1
brentuximab 1
vedotin 1
monotherapy 1
hodgkin 1
lymphoma 2
patients 2
aged 1
years 1
older 1
bendamustine 1
rituximabrefractory 1
indolent 1
transformed 1
nonhodgkins 1
results 1
ii 1
multicenter 1
singleagent 1
